Cutaneous Lymphocytic Vasculitis Due to Ibrutinib Therapy.

Actas Dermosifiliogr

Instituto Biosanitario de Salamanca (IBSAL), Spain; Servicio de Anatomía Patológica, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. Electronic address:

Published: February 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2023.04.039DOI Listing

Publication Analysis

Top Keywords

cutaneous lymphocytic
4
lymphocytic vasculitis
4
vasculitis ibrutinib
4
ibrutinib therapy
4
cutaneous
1
vasculitis
1
ibrutinib
1
therapy
1

Similar Publications

Primary cutaneous amoebiasis is rare, and typically affects immunocompromised patients and presents with unique clinical and histopathologic changes. Untreated, the infection could progress to involve the central nervous system, which is almost universally fatal. We present a case of primary cutaneous acanthamoebiasis in a patient with chronic lymphocytic leukemia on acalabrutinib.

View Article and Find Full Text PDF

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, originating from the malignant proliferation of squamous epithelial cells. However, its pathogenesis remains unclear. To further explore the mechanisms underlying cSCC, we analyzed the data from one single-cell RNA sequencing study and discovered a significant upregulation of tryptophan 2,3-dioxygenase (TDO2) in the cancer-associated fibroblasts (CAFs).

View Article and Find Full Text PDF
Article Synopsis
  • The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) are increasing, highlighting the urgent need for better prevention methods.
  • Topical treatments like calcipotriol and 5-fluorouracil (5-FU) can eliminate actinic keratosis (AK) lesions, but their exact mechanisms weren't clear until recent research.
  • A study shows that type 2 immunity, specifically the interaction between thymic stromal lymphopoietin (TSLP) and Th2 cells, is crucial for eliminating premalignant cells and could be targeted for cSCC prevention.
View Article and Find Full Text PDF

T helper 2 cell-directed immunotherapy eliminates precancerous skin lesions.

J Clin Invest

January 2025

Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.

The continuous rise in skin cancer incidence highlights an imperative for improved skin cancer prevention. Topical calcipotriol-plus-5-fluorouracil (calcipotriol-plus-5-FU) immunotherapy effectively eliminates precancerous skin lesions and prevents squamous cell carcinoma (SCC) in patients. However, its mechanism of action remains unclear.

View Article and Find Full Text PDF

MicroRNAs and long non-coding RNAs In T-cell lymphoma: Mechanisms, pathway, therapeutic opportunities.

Pathol Res Pract

December 2024

Department of Clinical Laboratory Science, College of Applied Medical Sciences, Al-Quwayiyah, Shaqra University, Riyadh, Saudi Arabia. Electronic address:

T-cell lymphomas represent non-Hodgkin lymphomas distinguished by the uncontrolled proliferation of malignant T lymphocytes. Classifying these neoplasms and the ongoing investigation of their underlying biological mechanisms remains challenging. Significant subtypes encompass peripheral T-cell lymphomas, anaplastic large-cell lymphomas, cutaneous T-cell lymphomas, and adult T-cell leukemia/lymphoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!